awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q37628728-22B3A090-9B27-46B6-A041-449F979180CF
Q37628728-22B3A090-9B27-46B6-A041-449F979180CF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37628728-22B3A090-9B27-46B6-A041-449F979180CF
Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors.
P2860
Q37628728-22B3A090-9B27-46B6-A041-449F979180CF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37628728-22B3A090-9B27-46B6-A041-449F979180CF
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2923e1ef54c1f03c2c6a303a04d7b8d5f0bbc5f3
P2860
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.